Shorter Radiation Treatment for Localised Prostate Cancer
Tests a shorter course of high-dose radiation in adults with localised prostate cancer.
Plain-language title generated from the registry record
Registry title: Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III)
Key facts
- Where
- Erfurt, Frankfurt am Main, Kiel, and Munich, GermanySee the 6 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has not spread outside the prostate. They would receive radiosurgery (focused radiation) in 3 sessions.
- Age
- 18 years or older
- Sex
- Men only
- Disease stage
- Prostate cancer confirmed by tissue test, still inside the prostate (cT1-T2c N0 M0). Gleason grade 7 or lower, ISUP Grade Group 1-3. PSA below 20 ng/ml. Prostate volume below 80 cm³. IPSS score 12 or lower.
- Earlier treatment
- People who had radiotherapy to the pelvis before cannot join. People who had a transurethral resection, laser enucleation or prostate ablation before cannot join.
Main reasons for not taking part
- Earlier radiotherapy to the pelvis
- Earlier transurethral resection, laser enucleation or prostate ablation
- Cannot have an MRI or fiducial marker implantation (for example gold allergy)
- Other illness thought to harm treatment compliance
- Legal incapacity or no informed consent
Read by machine on 12 November 2026.
Where in Germany
- CyberKnife Centrum MitteldeutschlandErfurt, GermanyContact: Hans-Ulrich Herold, MDTaking people
- Saphir Radiosurgery Center Frankfurt am MainFrankfurt am Main, GermanyContact: Christian Arnold, MDTaking people
- University Hospital FrankfurtFrankfurt am Main, GermanyContact: Oliver Blanck, PhDNo longer taking part
- University Medical Center Schleswig-HolsteinKiel, GermanyContact: Stefan Huttenlocher, MDTaking people
- Saphir Radiosurgery Center Norther GermanyKiel, GermanyContact: Oliver Blanck, PhDNo longer taking part
- European Radiosurgery Center MunichMunich, GermanyContact: Alexander Muacevic, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital Schleswig-Holstein
- Trial code
- NCT06914544
- Record updated
- 29 April 2026
- Original description
Hypofractionated radiosurgery with 5 fractions is considered standard of care for localized prostate cancer. The investigators initiated this multicenter phase II prospective trial to analyse feasibility (toxicity) of hypofractionated radiosurgery with 3 fractions in patients with localised prostate cancer under the hypothesis that the ratio of patients with late GU and GI toxicity ≥ grade 2 after 1 year amounts to 8.4% and 1.3% and is significant lower than 16.4% and 5.7% currently.Read full original descriptionShow less
Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III)
Hypofractionated radiosurgery with 5 fractions is considered standard of care for localized prostate cancer. The investigators initiated this multicenter phase II prospective trial to analyse feasibility (toxicity) of hypofractionated radiosurgery with 3 fractions in patients with localised prostate cancer under the hypothesis that the ratio of patients with late GU and GI toxicity ≥ grade 2 after 1 year amounts to 8.4% and 1.3% and is significant lower than 16.4% and 5.7% currently.
Inclusion: Localised, histopathologically confirmed Prostate Cancer (cT1-T2c N0 M0); Gleason-grade ≤7, ISUP Grade Group 1-3; Guideline-based staging; Age ≥ 18 years; PSA < 20 ng/ml; Volume of the prostate < 80 cm³; IPSS-Score ≤ 12; Written informed consent.
Exclusion: History of prior pelvic radiotherapy; Previous transurethral resection, laser enucleation or prostate ablation; Contraindication to MRI or Fiducial marker implantation (e.g. gold allergy); Relevant comorbidity thought to adversely affect treatment compliance; Legal incapacity or lack of informed consent.